Immunotherapies could target aggressive pancreatic cancer, research indicates
Scientists have discovered that hard-to-treat pancreatic cancer hijacks a key immune system response
Read More
Tag: TLR3
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
